NEOS Neos Therapeutics, Inc.

Subscribe to $NEOS

Neos Therapeutics, Inc.

Subscribe to $NEOS

$NEOS

Major Pharmaceuticals

Health Care

IPO Year: 2015

Exchange: NASDAQ

Recent Analyst Ratings for Neos Therapeutics, Inc.

Date	Price Target	Rating	Analyst

See more ratings

Neos Therapeutics, Inc. Press Releases

Fastest customizable press release news feed in the world

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 12, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system
3/12/21 9:04:16 AM ET
$NEOS
Major Pharmaceuticals
Health Care
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system
3/10/21 4:01:00 PM ET
$NEOS
Major Pharmaceuticals
Health Care
Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments
2/23/21 4:10:00 PM ET
$ACEV
$AYTU
$ASPL
$PACE
Semiconductors
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
– Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that the companies’ respective special meetings of stockholders related to the proposed merger between Aytu and Neos have been set f
2/10/21 8:00:00 AM ET
$AYTU
$NEOS
Biotechnology: Pharmaceutical Preparations
Health Care
Major Pharmaceuticals
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website at http://investors.neostx.com/ beginning Monday, January 11, 2021 at 6:00 a.m. ET. A replay of the webcast will be available on Neos’ website for 30 days. About Neos Therapeutics
1/4/21 4:01:00 PM ET
$NEOS
Major Pharmaceuticals
Health Care
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class prescription therapeutics and consumer health productsCompanies to host joint conference call today at 8:30 am ET ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company foc
12/10/20 8:00:00 AM ET
$AYTU
$NEOS
Biotechnology: Pharmaceutical Preparations
Health Care
Major Pharmaceuticals

Neos Therapeutics, Inc.

Recent Analyst Ratings for Neos Therapeutics, Inc.

Neos Therapeutics, Inc.

Recent Analyst Ratings for Neos Therapeutics, Inc.

Neos Therapeutics, Inc. FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

Neos Therapeutics, Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

Neos Therapeutics, Inc. SEC Filings

SEC Form EFFECT filed by Neos Therapeutics, Inc.

SEC Form EFFECT filed by Neos Therapeutics, Inc.

SEC Form EFFECT filed by Neos Therapeutics, Inc.

SEC Form EFFECT filed by Neos Therapeutics, Inc.

SEC Form 8-K filed by Neos Therapeutics, Inc.

SEC Form 425 filed by Neos Therapeutics, Inc.

SEC Form S-8 POS filed by Neos Therapeutics, Inc.

SEC Form S-8 POS filed by Neos Therapeutics, Inc.

SEC Form S-8 POS filed by Neos Therapeutics, Inc.

SEC Form S-8 POS filed by Neos Therapeutics, Inc.

Neos Therapeutics, Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: M John Limongelli disposed to the issuer $0 worth of Common Stock (83,015 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: W. Gerald Mclaughlin disposed to the issuer $0 worth of Common Stock (270,171 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: Beth Hecht disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: P. John Schmid disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: Bryant Fong disposed to the issuer $0 worth of Common Stock (24,953 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: M Linda Szyper disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: J Gregory Robitaille disposed to the issuer $0 worth of Common Stock (79,130 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: L Alan Heller disposed to the issuer $0 worth of Common Stock (446,819 units at $0.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: I Richard Eisenstadt disposed to the issuer $0 worth of Common Stock (126,245 units at $0.00), decreasing direct ownership by 100% to 0 units

Neos Therapeutics, Inc. Press Releases

Fastest customizable press release news feed in the world

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company